Future Vaccine Growth Could Come From Recent Biotech Entrants – Tufts
Executive Summary
The potential to create novel, innovative products has made the vaccine market more attractive in recent years, drawing new entrants as well as a resurgence of interest from traditional vaccine manufacturers, Tufts Center for the Study of Drug Development Director Kenneth Kaitin suggests
You may also be interested in...
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Novartis’ New Vaccine Division Takes On Evolving Market
Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said